T2 Biosystems to Share Early Data at the World Anti-Microbial Resistance Congress (November 7-8, 2019)
November 07 2019 - 7:30AM
T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the development
of innovative diagnostic products for critical unmet needs in
healthcare, announced today that it will be highlighting its
portfolio and pipeline of products in a keynote presentation at the
World Anti-Microbial Resistance Congress, which will take place in
Washington, DC, on November 7 and 8.
The Company will participate in two speaking events
at the congress. Sandy Estrada, PharmD, BCPS, Vice President of
Medical Affairs, will moderate the panel, “Evaluating Novel
Diagnostics for Hospital Use and Uptake in the
Clinic–Considerations for Cost, Personnel Training, and
Microbiologist Collaboration,” on November 7 at 3:55 p.m. Chief
Scientific Officer Tom Lowery, Ph.D., will deliver the keynote
address, titled, “The Impact of Rapid, Direct-from-blood
Diagnostics in Enabling Changes in Clinical Decisions and Improving
Outcomes,” on November 8 at 9:25 a.m.
“Antimicrobial resistance is no longer an emerging
threat – it is a very real, clear and present danger to public
health, making it important for professionals in the infectious
disease industry to seriously consider all types of solutions to
this issue. These solutions include, among others, rapid
diagnostics of bloodstream infections and rapid resistance gene
detection technology that can help improve outcomes for those at
greatest risk,” said Dr. Lowery.
Dr. Lowery continued, “My colleagues and I are
looking forward to sharing early data that demonstrates how culture
independent diagnostics can help enable quicker targeted treatment,
especially for antibiotic resistant organisms, and ultimately help
in the fight against antimicrobial resistance.”
The T2Resistance Panel RUO identifies 13 of the
most serious resistance genes on the antibiotic-resistance threat
list published by the Centers for Disease Control and Prevention
(CDC), including genes indicating resistance to common empiric
antibiotic therapies such as carbapenems, vancomycin, penicillin
and more. It is the first system that can detect resistance markers
directly from whole blood—in three to five hours.
The T2Resistance Panel RUO has been the center of
many recent accolades for T2 Biosystems. The panel was recently the
first diagnostic to graduate from the portfolio of CARB-X, a global
non-profit partnership dedicated to accelerating early development
antibacterial R&D to address the rising global threat of
drug-resistant bacteria. It also received Breakthrough Device
designation by the Food and Drug Administration (FDA) earlier this
year.
The panel utilizes the same T2Dx® Instrument as the
T2Bacteria® and T2Candida® Panels – the only FDA-cleared panels
that can detect sepsis-causing pathogens directly from a patient’s
blood sample, without the need to wait for a blood culture. A
positive blood culture takes one to five or more days before
subculture and antimicrobial susceptibility testing (AST) or
genomic testing can commence, which is the current pathway to
identifying antibiotic resistance – the conventional method that T2
Biosystems aims to circumvent to improve clinical outcomes.
About T2 Biosystems T2
Biosystems, a leader in the development and commercialization of
innovative medical diagnostic products for critical unmet needs in
healthcare, is dedicated to improving patient care and reducing the
cost of care by helping clinicians effectively treat patients
faster than ever before. T2 Biosystems’ products include the T2Dx®
Instrument, T2Candida® Panel, and T2Bacteria® Panel, which was
recently announced as the first and only in-vitro diagnostic test
to receive approval for a New Technology Add-on Payment (NTAP) by
CMS, are powered by the proprietary T2 Magnetic Resonance (T2MR®)
technology. T2 Biosystems has an active pipeline of future
products, including products for the detection of additional
species and antibiotic resistance markers of sepsis pathogens, and
tests for Lyme disease.
Forward-Looking Statements This
press release contains forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
All statements contained in this press release that do not relate
to matters of historical fact should be considered forward-looking
statements, including, without limitation, statements regarding
additional patients, timing of testing patients, anticipated
product benefits, strategic priorities, product expansion or
opportunities, growth expectations or targets, timing of FDA
filings or clearances and anticipated operating expenses, as well
as statements that include the words “expect,” “intend,” “plan”,
“believe”, “project”, “forecast”, “estimate,” “may,” “should,”
“anticipate,” and similar statements of a future or forward looking
nature. These forward-looking statements are based on management's
current expectations. These statements are neither promises nor
guarantees, but involve known and unknown risks, uncertainties and
other important factors that may cause actual results, performance
or achievements to be materially different from any future results,
performance or achievements expressed or implied by the
forward-looking statements, including, but not limited to, (i) any
inability to (a) realize anticipated benefits from commitments,
contracts or products; (b) successfully execute strategic
priorities; (c) bring products to market; (d) expand product usage
or adoption; (e) obtain customer testimonials; (f) accurately
predict growth assumptions; (g) realize anticipated revenues; (h)
incur expected levels of operating expenses; or (i) increase the
number of high-risk patients at customer facilities; (ii) failure
of early data to predict eventual outcomes; (iii) failure to
make or obtain anticipated FDA filings or clearances within
expected time frames or at all; or (iv) the factors discussed under
Item 1A. "Risk Factors" in the company's Annual Report on Form 10-K
for the year ended December 31, 2018, filed with the U.S.
Securities and Exchange Commission, or SEC, on March 14, 2019, and
other filings the company makes with the SEC from time to
time. These and other important factors could cause actual
results to differ materially from those indicated by the
forward-looking statements made in this press release. Any such
forward-looking statements represent management's estimates as of
the date of this press release. While the company may elect to
update such forward-looking statements at some point in the future,
unless required by law, it disclaims any obligation to do so, even
if subsequent events cause its views to change. Thus, no one should
assume that the Company’s silence over time means that actual
events are bearing out as expressed or implied in such
forward-looking statements. These forward-looking statements should
not be relied upon as representing the company's views as of any
date subsequent to the date of this press release.
Media Contact: Gina
Kent, Vault Communications gkent@vaultcommunications.com
610-455-2763
Investor Contact: Zack
Kubow, W2O Group zkubow@w2ogroup.com 415-658-6436
T2 Biosystems (NASDAQ:TTOO)
Historical Stock Chart
From Mar 2024 to Apr 2024
T2 Biosystems (NASDAQ:TTOO)
Historical Stock Chart
From Apr 2023 to Apr 2024